Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Bill: Senate v. House

This article was originally published in The Gray Sheet

Executive Summary

FDA user fee reauthorization and reform bills approved in the House and Senate have close alignment on many issues of relevance to the device industry, but also maintain some substantive differences, as outlined in the chart below.

You may also be interested in...



Final UDI Rule Date Uncertain, But Firms Should Prep Now, FDA Says

FDA likely won’t meet a May 2013 statutory deadline to issue final regulations for unique device identifiers, but that does not mean companies should delay efforts to comply. And firms should not rely on expected exemptions to the UDI mandate, an agency official said.

Congress Enters Final Stages On FDA Reform Bill

Legislative leaders say they remain on track to send FDA user fee reauthorization and reform legislation for the president’s signature by the end of June following House passage of bill.

Congress Enters Final Stages On FDA Reform Bill

Legislative leaders say they remain on track to send FDA user fee reauthorization and reform legislation for the president’s signature by the end of June following House passage of bill.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel